Debio 025 - Debiopharm

Home » Media » Press Releases

Debio 025

Date	Article Title
09 Feb 2010	Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -
30 Apr 2009	Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb study after record time patient randomisation
28 Apr 2009	Clinical Update – Debio 025 in Hepatitis C - Debiopharm presents promising phase IIa results showing potent antiviral activity
23 Jan 2009	Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue
28 Apr 2008	Clinical Update – Debio 025 in Hepatitis C - Presentation of Phase IIa Efficacy Results
18 Apr 2007	Clinical update - Debio 025 cyclophilin inhibitor for the treatment of HCV - A unique viral kinetics
31 Oct 2006	Debiopharm presents new data confirming anti-HCV activity of cyclophilin inhibitor for Debio-025
09 Feb 2006	Debiopharm S.A. presented results of a double-blind placebo-controlled study on first-in-class Debio-025 in HIV-1-infected subjects
06 Oct 2004	New Data presented on Debiopharm´s Debio-025 at the 11th International Symposium on Hepatits C virus and related viruses

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group